6 unchanged sentences
There are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures.
+Added: Changes in Internal Control Over Financial Reporting
+Added: There have been no changes in the Company's internal control over financial reporting during the quarter ended December 31, 2024 that have materially affected, or that are reasonably likely to materially affect, the Company's internal control over financial reporting.
Management Report on Internal Control over Financial Reporting
9 unchanged sentences
Based on this assessment, management concluded that, as of December 31, 2024, the Company’s internal control over financial reporting was effective.
−Removed: This Annual Report on Form 10-K does not include, and we were not required to include, an attestation report of our independent registered public accounting firm on the effectiveness of our internal control over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act of 2002 for as long as we remain an “emerging growth company” as defined in the Jumpstart Our Business Startups Act.
−Removed: Changes in Internal Control Over Financial Reporting
−Removed: There have been no changes in the Company's internal control over financial reporting during the quarter ended December 31, 2023 that have materially affected, or that are reasonably likely to materially affect, the Company's internal control over financial reporting.
−Removed: VIEMED HEALTHCARE, INC.
−Removed: (Tabular dollar amounts expressed in thousands of U.S.
−Removed: Dollars, except per share amounts)
−Removed: December 31, 2023 and 2022
+Added: The effectiveness of the Company's internal control over financial reporting as of December 31, 2024 has been audited by Ernst & Young LLP, an independent registered public accounting firm, as stated in their attestation report included in this Annual Report on Form 10-K, which expresses an unqualified opinion on the effectiveness of the Company's internal control over financial reporting as of December 31, 2024.
+Added: Report of Independent Registered Public Accounting Firm
+Added: To the Shareholders and the Board of Directors of Viemed Healthcare, Inc.
+Added: Opinion on Internal Control Over Financial Reporting
+Added: We have audited Viemed Healthcare, Inc.’s internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria).
+Added: In our opinion, Viemed Healthcare, Inc.
+Added: (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024, based on the COSO criteria.
+Added: We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2024 and 2023, the related consolidated statements of income and comprehensive income, changes in shareholders’ equity and cash flows for each of the three years in the period ended December 31, 2024, and the related notes and our report dated March 10, 2025 expressed an unqualified opinion thereon.
+Added: Basis for Opinion
+Added: The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management Report on Internal Control over Financial Reporting.
+Added: Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit.
+Added: We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S.
+Added: federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
+Added: We conducted our audit in accordance with the standards of the PCAOB.
+Added: Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.
+Added: Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances.
+Added: We believe that our audit provides a reasonable basis for our opinion.
+Added: Definition and Limitations of Internal Control Over Financial Reporting
+Added: A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.
+Added: A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;
+Added: (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company;
+Added: and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
+Added: Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.
+Added: Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
+Added: /s/ Ernst & Young LLP
+Added: New Orleans, Louisiana
+Added: March 10, 2025
Other Information
3 unchanged sentences
Not applicable.
−Removed: VIEMED HEALTHCARE, INC.
−Removed: (Tabular dollar amounts expressed in thousands of U.S.
−Removed: Dollars, except per share amounts)
−Removed: December 31, 2023 and 2022
Directors, Executive Officers and Corporate Governance
17 unchanged sentences
• Report of Independent Registered Public Accounting Firm
−Removed: • Balance Sheets as of December 31, 2023 and 2022
−Removed: • Statements of Operations for the years ended December 31, 2023 and 2022
−Removed: • Statements of Shareholders’ Equity for the years ended December 31, 2023 and 2022
−Removed: • Statements of Cash Flows for the years ended December 31, 2023 and 2022
+Added: • Consolidated Balance Sheets as of December 31, 2024 and 2023
+Added: • Consolidated Statements of Income and Comprehensive Income for the years ended December 31, 2024, 2023, and 2022
+Added: • Consolidated Statements of Changes in Shareholders’ Equity for the years ended December 31, 2024, 2023, and 2022
+Added: • Consolidated Statements of Cash Flows for the years ended December 31, 2024, 2023, and 2022
Financial Statement Schedules.
1 unchanged sentence
Unless otherwise indicated, all documents incorporated into this Annual Report on Form 10-K by reference to a document filed with the SEC pursuant to the Exchange Act are located under SEC file number 001-38973.
−Removed: VIEMED HEALTHCARE, INC.
−Removed: (Tabular dollar amounts expressed in thousands of U.S.
−Removed: Dollars, except per share amounts)
−Removed: December 31, 2023 and 2022
Exhibit Number Exhibit Title
6 unchanged sentences
4.1 Description of Registrant's Securities.
+Added: Incorporated by reference to Exhibit 4.1 to the Company’s Annual Report on Form 10-K filed on March 6, 2024.
10.1 Credit Agreement, dated November 29, 2022, among Viemed, Inc., as borrower, certain subsidiaries of Viemed, Inc., as guarantors, the lenders from time to time party thereto, and Regions Bank, as administrative agent and collateral agent.
27 unchanged sentences
+10.12 Viemed Healthcare, Inc.
−Removed: (Tabular dollar amounts expressed in thousands of U.S.
−Removed: Dollars, except per share amounts)
−Removed: December 31, 2023 and 2022
−Removed: +10.12 Viemed Healthcare, Inc.
2020 Long Term Incentive Plan.
8 unchanged sentences
Incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed on November 2, 2021.
+Added: 10.17 First Amendment to Credit Agreement dated November 29, 2022, among Viemed Inc.
+Added: as borrower, certain subsidiaries of Viemed, Inc., as guarantors, the lenders from time to time party thereto, and Regions Bank, as administrative agent and collateral agent, effective May 28, 2024.
+Added: Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on May 29, 2024.
+Added: Viemed Healthcare, Inc.
+Added: 2024 Long Term Incentive Plan.
+Added: Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on June 6, 2024.
+Added: Vi emed He althcare, Inc .
+Added: Insider Trading Pol icy, dated January 21, 2025.
*21.1 Subsidiaries of the Registrant.
8 unchanged sentences
Executive Compensation Clawback Policy, as adopted on November 9, 2023.
+Added: Incorporated by reference to Exhibit 97.1 to the Company’s Annual Report on Form 10-K filed on March 6, 2024.
*101.INS Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
11 unchanged sentences
Form 10-K Summary
−Removed: VIEMED HEALTHCARE, INC.
−Removed: (Tabular dollar amounts expressed in thousands of U.S.
−Removed: Dollars, except per share amounts)
−Removed: December 31, 2023 and 2022
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
25 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.